Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice
NCT ID: NCT01212601
Last Updated: 2012-11-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
203 participants
OBSERVATIONAL
2011-01-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A patient who is considered as ethnic Chinese
* Provision of subject informed consent
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aixia Wang, Prof.
Role: PRINCIPAL_INVESTIGATOR
Peiking Union Medical College Hospital
Karen Atkin
Role: STUDY_DIRECTOR
AstraZeneca
Mentha Wang
Role: STUDY_CHAIR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Beijing, Beijing Municipality, China
Research Site
Fuzhou, Fujian, China
Research Site
Xiamen, Fujian, China
Research Site
Zhangzhou, Fujian, China
Research Site
Guangzhou, Guangdong, China
Research Site
Xingtai, Hebei, China
Research Site
Haerbing, Heilongjiang, China
Research Site
Zhenzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Changzhou, Jiangsu, China
Research Site
Nanjing, Jiangsu, China
Research Site
Nantong, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
Research Site
Dalian, Liaoning, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Kunming, Yunnan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-ICN-DUM-2010/1
Identifier Type: -
Identifier Source: org_study_id